Simulating the Control Arm: Virtual Patients at the Trial Bottleneck
Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.
Clinical trials remain the most expensive bottleneck in drug development. And although this stage comes after all the high tech pharmacological tinkering is over, a trial conduct runs into its own obstacles.
Read this Pro article free
Subscribe to BiopharmaTrend Insider, our free biweekly briefing on what matters in tech and bio, and get one free Pro article every month, starting with this one.
Insider arrives every two weeks, plus a short note when we publish a new deep dive. Unsubscribe anytime. Articles you unlock stay unlocked.
Already subscribed? Sign in here.